Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

First human safety and effectiveness study of defibrillation with a novel patch wearable cardioverter-defibrillator

M. Chovanec, J. Petrů, P. Hála, S. Kralovec, AB. Thakkar, K. Mathews, M. Dinger, S. Ullery, ZJ. Eapen, UN. Kumar, P. Neužil

. 2024 ; 26 (7) : . [pub] 20240702

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24019816

Grant support
Element Science, Inc

AIMS: Wearable cardioverter-defibrillators (WCDs) are indicated in patients at risk of sudden cardiac arrest who are not immediate candidates for implantable defibrillator therapy. Limitations of existing WCDs include poor compliance and high false alarm rates. The Jewel is a novel patch-WCD (P-WCD) that addresses these limitations with an adhesive-based design for near-continuous wear and a machine learning algorithm designed to minimize inappropriate detections. This was a first-in-human study of the Jewel P-WCD conducted in an electrophysiology (EP) lab to determine the safety and effectiveness of the device in terminating ventricular tachycardia/ventricular fibrillation (VT/VF) with a single shock. The aim was to evaluate the safety and effectiveness of terminating VT/VF with a single shock using the Jewel P-WCD. METHODS AND RESULTS: This was a first-in-human, prospective, single-arm, single-centre study in patients scheduled for an EP procedure in which VT/VF was expected to either spontaneously occur or be induced. The Jewel P-WCD was placed on consented patients; upon confirmation of VT/VF, a single shock (150 J) was delivered via the device. A group sequential design and Pocock alpha spending function was used to measure the observed proportion of successful VT/VF single-shock terminations. The endpoint was achieved if the lower confidence limit exceeded the performance goal of 62%, using a one-sided lower 97.4% exact confidence bound. Of 18 eligible subjects, 16 (88.9%, 97.4% confidence bound: 65.4%) were successfully defibrillated with a single shock, exceeding the primary endpoint performance goal with no adverse events. CONCLUSION: This first-in-human evaluation of the Jewel P-WCD demonstrated the safety and effectiveness of terminating VT/VF. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov/; Unique identifier: NCT05490459.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019816
003      
CZ-PrNML
005      
20241024110944.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euae189 $2 doi
035    __
$a (PubMed)39001864
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Chovanec, Milan $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic
245    10
$a First human safety and effectiveness study of defibrillation with a novel patch wearable cardioverter-defibrillator / $c M. Chovanec, J. Petrů, P. Hála, S. Kralovec, AB. Thakkar, K. Mathews, M. Dinger, S. Ullery, ZJ. Eapen, UN. Kumar, P. Neužil
520    9_
$a AIMS: Wearable cardioverter-defibrillators (WCDs) are indicated in patients at risk of sudden cardiac arrest who are not immediate candidates for implantable defibrillator therapy. Limitations of existing WCDs include poor compliance and high false alarm rates. The Jewel is a novel patch-WCD (P-WCD) that addresses these limitations with an adhesive-based design for near-continuous wear and a machine learning algorithm designed to minimize inappropriate detections. This was a first-in-human study of the Jewel P-WCD conducted in an electrophysiology (EP) lab to determine the safety and effectiveness of the device in terminating ventricular tachycardia/ventricular fibrillation (VT/VF) with a single shock. The aim was to evaluate the safety and effectiveness of terminating VT/VF with a single shock using the Jewel P-WCD. METHODS AND RESULTS: This was a first-in-human, prospective, single-arm, single-centre study in patients scheduled for an EP procedure in which VT/VF was expected to either spontaneously occur or be induced. The Jewel P-WCD was placed on consented patients; upon confirmation of VT/VF, a single shock (150 J) was delivered via the device. A group sequential design and Pocock alpha spending function was used to measure the observed proportion of successful VT/VF single-shock terminations. The endpoint was achieved if the lower confidence limit exceeded the performance goal of 62%, using a one-sided lower 97.4% exact confidence bound. Of 18 eligible subjects, 16 (88.9%, 97.4% confidence bound: 65.4%) were successfully defibrillated with a single shock, exceeding the primary endpoint performance goal with no adverse events. CONCLUSION: This first-in-human evaluation of the Jewel P-WCD demonstrated the safety and effectiveness of terminating VT/VF. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov/; Unique identifier: NCT05490459.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nositelná elektronika $7 D000076251
650    12
$a fibrilace komor $x terapie $x diagnóza $7 D014693
650    12
$a elektrická defibrilace $x přístrojové vybavení $x škodlivé účinky $7 D004554
650    _2
$a lidé středního věku $7 D008875
650    12
$a komorová tachykardie $x terapie $x diagnóza $x patofyziologie $7 D017180
650    12
$a defibrilátory $7 D047548
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
650    _2
$a senioři $7 D000368
650    _2
$a design vybavení $7 D004867
650    _2
$a dospělí $7 D000328
650    _2
$a náhlá srdeční smrt $x prevence a kontrola $7 D016757
655    _2
$a časopisecké články $7 D016428
700    1_
$a Petrů, Jan $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Hála, Pavel $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic $1 https://orcid.org/0000000291035406 $7 xx0232154
700    1_
$a Kralovec, Stepan $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Thakkar, Anjali B $u Division of Cardiology, Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA
700    1_
$a Mathews, Kiran $u Element Science, Inc., Redwood City, CA, USA $1 https://orcid.org/0009000512915042
700    1_
$a Dinger, Maarten $u Element Science, Inc., Redwood City, CA, USA
700    1_
$a Ullery, Steven $u North American Science Associates, Walnut Creek, CA, USA
700    1_
$a Eapen, Zubin J $u Element Science, Inc., Redwood City, CA, USA
700    1_
$a Kumar, Uday N $u Element Science, Inc., Redwood City, CA, USA
700    1_
$a Neužil, Petr $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic $1 https://orcid.org/0000000343348165
773    0_
$w MED00149837 $t Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology $x 1532-2092 $g Roč. 26, č. 7 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39001864 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110938 $b ABA008
999    __
$a ok $b bmc $g 2202189 $s 1231789
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 7 $e 20240702 $i 1532-2092 $m Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology $n Europace $x MED00149837
GRA    __
$p Element Science, Inc
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options